Avantor, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Avantor, Inc. on April 22, 2020. The report discloses a corporate governance event regarding the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change disclosed is the appointment of Michael Severino as a Class II independent director, effective April 22, 2020. This appointment fills a vacant board seat. Dr. Severino brings significant experience from the biopharmaceutical sector, having served as Vice Chairman and President of AbbVie Inc. since 2018 and previously holding leadership roles at Amgen, Inc.
Compensation and Governance
Dr. Severino is eligible for standard non-employee director compensation, which includes:
- An annual cash retainer of $75,000 (prorated for the 2020 fiscal year).
- A grant of restricted stock units valued at $200,000 (prorated for the 2020 fiscal year), vesting in full one year from the grant date subject to continued service.
The Board determined that Dr. Severino meets the independence standards of the New York Stock Exchange. No material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.
Investor Verification Checklist
- Verify the effective date of Dr. Severino's board term (expires at the 2021 Annual Meeting).
- Confirm the vesting schedule and conditions for the $200,000 restricted stock unit grant.
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.
- Check for any subsequent filings regarding the composition of the Board's committees following this appointment.